Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic.

Published bySherilyn Osborne Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic."— Presentation transcript:

1 Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition.
MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. (A) Optical image shows the tissue sample that was analyzed at the demarcated regions (1 to 5) using a 1.5-mm-diameter MasSpec Pen. After the MasSpec Pen analysis, the tissue sample was frozen, sectioned, and H&E-stained. An optical image of the H&E-stained tissue section obtained at region 3 is shown (inset), presenting a mixed histologic composition including cancer and adjacent normal stroma tissue. (B) The MasSpec Pen negative ion mode mass spectra are shown for regions 1 (normal stroma; average of n = 3 mass spectra), 3 (mixture of normal stroma and cancer; average of n = 3 mass spectra), and 5 (cancer; average of n = 3 mass spectra). (C) Table listing the pathologic diagnosis of the five regions analyzed and the Lasso prediction results. Jialing Zhang et al., Sci Transl Med 2017;9:eaan3968 Published by AAAS

Download ppt "Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic."

Similar presentations

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.
First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.
Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.

Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.
Fig. 1. Schematic representation of the MasSpec Pen system and operational steps. Schematic representation of the MasSpec Pen system and operational steps.

Fig. 1. Schematic representation of the MasSpec Pen system and operational steps. Schematic representation of the MasSpec Pen system and operational steps.
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 4. Hydrogel particle size and gelation mechanism.

Fig. 4. Hydrogel particle size and gelation mechanism.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.
Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 1 DMF promotes viral infection.

Fig. 1 DMF promotes viral infection.

Similar presentations

Ads by Google